Search

Aims Primary acute heart failure (AHF) is a common cause of hospitalization. AHF may also develop postoperatively (pAHF). The aim of this study was to assess the incidence, phenotypes, determinants and outcomes of pAHF following non-cardiac surgery.Methods and results A total of 9164 consecutive high-risk patients undergoing 11 262 non-cardiac inpatient surgeries were prospectively included. The incidence, phenotypes, determinants and outcome of pAHF, centrally adjudicated by independent cardiologists, were determined. The incidence of pAHF was 2.5% (95% confidence interval [CI] 2.2-2.8%); 51% of pAHF occurred in patients without known heart failure (de novo pAHF), and 49% in patients with chronic heart failure. Among patients with chronic heart failure, 10% developed pAHF, and among patients without a history of heart failure, 1.5% developed pAHF. Chronic heart failure, diabetes, urgent/emergent surgery, atrial fibrillation, cardiac troponin elevations above the 99th percentile, chronic obstructive pulmonary disease, anaemia, peripheral artery disease, coronary artery disease, and age, were independent predictors of pAHF in the logistic regression model. Patients with pAHF had significantly higher all-cause mortality (44% vs. 11%, p < 0.001) and AHF readmission (15% vs. 2%, p < 0.001) within 1 year than patients without pAHF. After Cox regression analysis, pAHF was an independent predictor of all-cause mortality (adjusted hazard ratio [aHR] 1.7 [95% CI 1.3-2.2]; p < 0.001) and AHF readmission (aHR 2.3 [95% CI 1.5-3.7]; p < 0.001). Findings were confirmed in an external validation cohort using a prospective multicentre cohort of 1250 patients (incidence of pAHF 2.4% [95% CI 1.6-3.3%]).Conclusions Postoperative AHF frequently developed following non-cardiac surgery, being de novo in half of cases, and associated with a very high mortality., Funding Agencies|Swiss National Science Foundation; Swiss Heart Foundation; University Hospital Basel; University of Basel; AstraZeneca; Abbott; Roche; Clinical Research Program of the University of Basel; Spezialprogramm Nachwuchsforderung Klinische Forschung; Forderung Exzellenter Junger Forschender; Forschung fond Kantonsspital Aarau; Swiss Academy of Medical Sciences; Bangerter Foundation; Fundacao de Amparo a Pesquisa do Estado de Sao Paulo; Brazil [FAPESP] [2015/23731-6]; Swedish Research Council [2019-02833]; South Eastern Sweden Research Council [746981, 712291]; LinkopingUniversity-Region_Osterg_otland ALF [687681, 792291]

Aims Perioperative myocardial infarction/injury (PMI) is a surprisingly common yet difficult-to-predict cardiac complication in patients undergoing noncardiac surgery. We aimed to assess the incremental value of preoperative cardiac troponin (cTn) concentration in the prediction of PMI. Methods and results Among prospectively recruited patients at high cardiovascular risk (age >= 65 years or >= 45 years with preexisting cardiovascular disease), PMI was defined as an absolute increase in high-sensitivity cTnT (hs-cTnT) concentration of >= 14 ng/L (the 99th percentile) above the preoperative concentration. Perioperative myocardial infarction/injury was centrally adjudicated by two independent cardiologists using serial measurements of hs-cTnT. Using logistic regression, three models were derived: Model 1 including patient- and procedure-related information, Model 2 adding routinely available laboratory values, and Model 3 further adding preoperative hs-cTnT concentration. Models were also compared vs. preoperative hs-cTnT alone. The findings were validated in two independent cohorts. Among 6944 patients, PMI occurred in 1058 patients (15.2%). The predictive accuracy as quantified by the area under the receiver operating characteristic curve was 0.73 [95% confidence interval (CI) 0.71-0.74] for Model 1, 0.75 (95% CI 0.74-0.77) for Model 2, 0.79 (95% CI 0.77-0.80) for Model 3, and 0.74 for hs-cTnT alone. Model 3 included 10 preoperative variables: age, body mass index, known coronary artery disease, metabolic equivalent >4, risk of surgery, emergency surgery, planned duration of surgery, haemoglobin, platelet count, and hs-cTnT. These findings were confirmed in both independent validation cohorts (n = 722 and n = 966). Conclusion Preoperative cTn adds incremental value above patient- and procedure-related variables as well as routine laboratory variables in the prediction of PMI., Funding Agencies|Swiss National Science Foundation; University Basel; Universitatsspital Basel; Swiss Heart Foundation; Roche Diagnostics; Abbott; Astra Zeneca Schweiz; Cardiovascular Research Foundation Basel; Fundacao de Amparo a Pesquisa do Estado de Sao Paulo, Brazil (FAPESP) [2015/23731-6]

Introduction: Involvement of major vascular structures has been considered a limiting factor for resecting advanced tumors. The objective of this study was to evaluate the outcome after concomitant retroperitoneal tumor and vascular resection with prosthetic replacement of the aorta/vena cava. Methods: The authors reviewed a 5-year series of eight patients with a median age of 50 years (range 11-68 years) who had undergone resection of a retroperitoneal tumor and concomitant resection and replacement of the abdominal aorta, inferior vena cava, or both. The histologic diagnoses were sarcoma (five patients), teratoma (one), transitional cell carcinoma (one), and ganglioneuroma (one). The main outcome measures were early (< 30 days) and late (≥ 30 days) surgical morbidity and mortality. Secondary endpoints were vascular graft patency and tumor-free survival. Two patients underwent combined graft replacement of the aorta and vena cava. Single aortic and vena cava graft replacement were each done in three patients. Results: Two patients showed early surgical morbidity necessitating reoperation for a thrombotic graft occlusion. No patient died during the early course of the follow-up. During a median follow-up of 14 months (range 1-56 months), two patients had late surgical morbidity. The median tumor-free survival for patients with malignancy was 14 months (range 1-54 months). One patient developed locoregional tumor recurrence, and two developed distant metastases. The median survival for patients with malignancy was 14 months (range 1-60 months). Conclusions: An aggressive surgical approach for otherwise unresectable retroperitoneal tumors with vascular resection and prosthetic vascular replacement is justified in selected cases and has acceptable morbidity and mortality

Background: The appropriate role for surgery and endovascular therapy for severe intermittent claudication (IC) remains controversial. We present our results after infrainguinal autogenous bypass for severe IC more than 10years ago giving a reasoned argument to perform vein bypass as the primary procedure for severe IC. Methods: Our prospectively designed database includes more than 1,000 infrainguinal bypasses following an all-autogenous policy. For this review only patients operated on for severe IC at least 10years ago were included. The primary end points were survival and primary and assisted-primary patency rates. Results: From October 1988 until December 2000, 124 bypasses for IC were performed. Ninety-five patients were male and the mean age was 64.5±10.8years. Survival after 10years was 50.3% according to life table analysis. Forty bypasses were to the supragenicular artery, 62 to the infragenicular popliteal artery, and 22 to the tibial artery. Thirty-day mortality was 0.8% (1 patient). The primary patency rate after 10years was 63.5% and the assisted-primary patency rate 87.3%. Conclusion: Infrainguinal venous bypass for severe IC has excellent long-term results. Our results are strong arguments against the liberal use of stenting long lesions of the femoropopliteal artery. Venous bypass remains the primary procedure for TASC C and D lesions in claudicants

Background: The appropriate role for surgery and endovascular therapy for severe intermittent claudication (IC) remains controversial. We present our results after infrainguinal autogenous bypass for severe IC more than 10years ago giving a reasoned argument to perform vein bypass as the primary procedure for severe IC. Methods: Our prospectively designed database includes more than 1,000 infrainguinal bypasses following an all-autogenous policy. For this review only patients operated on for severe IC at least 10years ago were included. The primary end points were survival and primary and assisted-primary patency rates. Results: From October 1988 until December 2000, 124 bypasses for IC were performed. Ninety-five patients were male and the mean age was 64.5±10.8years. Survival after 10years was 50.3% according to life table analysis. Forty bypasses were to the supragenicular artery, 62 to the infragenicular popliteal artery, and 22 to the tibial artery. Thirty-day mortality was 0.8% (1 patient). The primary patency rate after 10years was 63.5% and the assisted-primary patency rate 87.3%. Conclusion: Infrainguinal venous bypass for severe IC has excellent long-term results. Our results are strong arguments against the liberal use of stenting long lesions of the femoropopliteal artery. Venous bypass remains the primary procedure for TASC C and D lesions in claudicants

Introduction: Involvement of major vascular structures has been considered a limiting factor for resecting advanced tumors. The objective of this study was to evaluate the outcome after concomitant retroperitoneal tumor and vascular resection with prosthetic replacement of the aorta/vena cava. Methods: The authors reviewed a 5-year series of eight patients with a median age of 50 years (range 11-68 years) who had undergone resection of a retroperitoneal tumor and concomitant resection and replacement of the abdominal aorta, inferior vena cava, or both. The histologic diagnoses were sarcoma (five patients), teratoma (one), transitional cell carcinoma (one), and ganglioneuroma (one). The main outcome measures were early (< 30 days) and late (≥ 30 days) surgical morbidity and mortality. Secondary endpoints were vascular graft patency and tumor-free survival. Two patients underwent combined graft replacement of the aorta and vena cava. Single aortic and vena cava graft replacement were each done in three patients. Results: Two patients showed early surgical morbidity necessitating reoperation for a thrombotic graft occlusion. No patient died during the early course of the follow-up. During a median follow-up of 14 months (range 1-56 months), two patients had late surgical morbidity. The median tumor-free survival for patients with malignancy was 14 months (range 1-54 months). One patient developed locoregional tumor recurrence, and two developed distant metastases. The median survival for patients with malignancy was 14 months (range 1-60 months). Conclusions: An aggressive surgical approach for otherwise unresectable retroperitoneal tumors with vascular resection and prosthetic vascular replacement is justified in selected cases and has acceptable morbidity and mortality